Home » Burzynski Using UAB for Bioinformatics

Burzynski Using UAB for Bioinformatics

Sep 29, 2009

NEW YORK (GenomeWeb News) – The Burzynski Research Institute has struck a research agreement with the University of Alabama at Birmingham, under which the school will provide bioinformatics and data management support for the company's glioma treatment studies.

BRI, a Houston-based company focused on using genomics and epigenomics for cancer studies, said that UAB's Biostatistics and Bioinformatics Shared Facility (BBSF) will support its Phase I and Phase II protocol studies of Antineoplaston therapy, a treatment for gliomas.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Scan

An Expensive Deal

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Figuring Out Who It'll Work For

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

This Week in Nature

In Nature this week: paternal age associated with de novo mutations in children, and more.

Ye Old P-Value

Nature News writes that researchers are still wrangling over the role of the p-value.

What's Popular?

In Informatics

  1. Hearst Invests $75M in M2Gen

  2. Researchers Identify SNP Set, Develop QR Code to Distinguish Genome Samples

  3. Optalysys Readies Optical Sequencing Alignment for Market

    Premium

  4. Optalysys Raises $4M in Seed Funding Round

  5. NSGC Panelists Discuss Strategies to Convert Variants of Unknown Significance to Known Significance

Sponsorships

Privacy Policy.  Copyright © 2017 GenomeWeb LLC.  All Rights Reserved.